Vol. 12, No. 1, June 2025, ISSN: 2049-4963
© IJBMSP
www.ijbmsp.org

3D Printing as a Game-Changer in Drug Development

Nazar Muhammad[1], Umaima Khan[1], Sania Ikram[1], Haider Ali[2], Zubair Ahmed[2], Zoha Waheed Abbasi[1], Maryam Aftab[3*]

[1]Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Punjab, Pakistan

[2] Department of Pharmacy, Kohat University of Science and Technology, Kohat 26000, Khyber Pakhtunkhwa, Pakistan

[3] Department of Biosciences, COMSATS University, Islamabad

Email: maryambiochem88@gmail.com

Abstract – The emergence of 3D printing has marked a transformative shift in pharmaceutical technology, offering novel approaches to drug development, formulation, and delivery. By enabling the precise fabrication of complex drug delivery systems, 3D printing provides opportunities for personalized medication, improving patient-specific treatments and optimizing drug release profiles. This review explores various 3D printing technologies, such as Fused Deposition Modeling (FDM), Inkjet Printing, Stereolithography (SLA), and Selective Laser Sintering (SLS), highlighting their principles, applications, and associated challenges in pharmaceutical manufacturing. The integration of biodegradable polymers, functional excipients, and novel materials like nanocomposites further enhances the efficacy of printed formulations. Despite these advancements, the widespread adoption of 3D printing in drug development faces several technological, regulatory, and economic barriers including hardware limitations, material compatibility, and the lack of standardized regulatory frameworks. The stability and shelf-life of printed formulations remain critical concerns, requiring ongoing research to ensure long-term efficacy. Future directions for 3D printing in pharmaceuticals emphasize its potential for on-demand production, personalized therapies, and collaborative efforts between academia, industry, and regulatory bodies to establish consistent standards. As technology evolves, 3D printing is poised to play a pivotal role in the next-generation pharmaceutical ecosystem, providing innovative, patient-centered solutions for drug delivery and treatment optimization.

Keywords – 3D Printing, Additive Manufacturing, Drug Development, Drug Delivery Systems, Personalized Medicine, Pharmaceutical Manufacturing.

1. Introduction

The pharmaceutical industry has traditionally relied on standardized, large-scale manufacturing techniques to produce medicines. While this model has supported the mass distribution of essential drugs for decades, it also presents significant limitations, especially in today's era of precision medicine [1]. Conventional drug development is often characterized by long development cycles, high costs, and limited adaptability to individual patient needs. Most dosage forms are manufactured to suit an average patient, offering little flexibility in terms of dose adjustment, drug combination, or release behavior. As a result, personalized therapy an approach that considers genetic, physiological, and lifestyle factors remains difficult to implement using traditional methods [2, 3].

Moreover, modern healthcare increasingly demands more sophisticated drug delivery systems. From pediatric patients who require smaller doses in child-friendly forms to elderly populations who may benefit from multi-drug combinations in a single tablet, the need for customizable pharmaceutical solutions is growing rapidly [4, 5]. In addition, the rise of complex diseases such as cancer, neurological disorders, and chronic conditions has emphasized the importance of precise, targeted, and responsive drug delivery mechanisms [6, 7]. In response to these evolving demands, three-dimensional (3D) printing, also known as additive manufacturing, has emerged as a highly innovative and versatile technology in the pharmaceutical field. Originally developed for applications in engineering and prototyping, 3D printing has since made its way into healthcare, offering exciting possibilities in drug formulation and production [8, 9]. The core principle of 3D printing involves fabricating objects layer by layer using computer-aided design (CAD) models [10]. This technique allows for exceptional control over the geometry, internal structure, and composition of the printed product [11, 12].

When applied to pharmaceuticals, 3D printing enables the production of highly customized drug dosage forms. It allows precise control over drug content, shape, size, porosity, and release profiles [13-15]. This makes it particularly well-suited for creating personalized medicines, tailored to meet the specific needs of individual patients. For example, drugs can be printed in doses that exactly match a patient's metabolism or condition, and multi-drug combinations (polypills) can be designed to simplify treatment regimens and improve compliance [15-17]. One of the most significant milestones in this area was the U.S. FDA approval of Spritam® in 2015—the first 3D-printed drug on the market [17]. This event marked the beginning of a new era in pharmaceutical manufacturing, validating 3D printing as a viable and regulatory-compliant method for drug production [18, 19]. Since then, research in this field has expanded rapidly, exploring new materials, printing techniques, and applications in both industrial and clinical settings [20, 21].

The aim of this review is to provide a comprehensive overview of how 3D printing is transforming drug development . It will explore the key technologies used, the range of materials suitable for pharmaceutical printing, and the major application areas including personalized medicine, controlled release systems, and on-demand drug manufacturing. The review also discusses current regulatory considerations, notable case studies, recent advancements, and the challenges that must be addressed for widespread adoption. By analyzing the integration of 3D printing into pharmaceutical science, this article highlights the game-changing potential of this technology. As the demand for personalized, flexible, and efficient drug therapies grows, 3D printing stands out as a powerful tool to bridge the gap between industrial production and patient-centered care. The future of pharmaceutics may well be one where medicines are designed, printed, and delivered in a way that is truly tailored to the individual.

2. Principles and Types of 3D Printing Technologies

Additive manufacturing, or 3D printing, has emerged as a powerful tool in pharmaceutical sciences due to its precision, flexibility, and ability to fabricate complex drug delivery systems layer by layer [22, 23]. Unlike conventional manufacturing, which often involves compressing powders or casting molds, 3D printing enables the creation of tailored dosage forms directly from digital models. This shift from batch-wise production to on-demand fabrication supports the growing interest in personalized medicine, where drug formulations can be adjusted according to individual patient profiles, therapeutic needs, and release kinetics [24-26]. Several 3D printing techniques have been explored for pharmaceutical applications, each based on a unique working principle and suited to specific drug or formulation types as listed in table-1. Fused Deposition Modeling (FDM) is among the most widely used methods, where a thermoplastic filament is heated and extruded to form solid structures[27, 28]. It is particularly effective for producing customized oral tablets, though it requires heat-stable drugs. Inkjet printing, on the other hand, works by precisely depositing tiny droplets of drug-loaded solutions onto a substrate[29]. This method is ideal for producing thin films and low-dose formulations and operates at room temperature, preserving drug stability. Stereolithography (SLA) uses a UV laser to cure photosensitive resins into solid forms with high resolution, making it suitable for intricate structures like implants or microneedles, though material limitations and UV sensitivity of drugs are concerns [30, 31]. Selective Laser Sintering (SLS) employs a laser to fuse powder particles layer by layer, allowing the construction of porous structures without binders. This is beneficial for creating controlled-release formulations and implantable devices, but the high processing temperatures restrict its use to thermally stable compounds [32, 33]. Another promising technique is semi-solid extrusion (SSE), where gels or pastes are extruded at low temperatures, making it ideal for thermolabile drugs and formulations like hydrogels, topicals, and pediatric dosage forms [34]. In addition, hybrid methods combining features of multiple techniques are being developed to expand design and formulation capabilities [35]. Each technology presents a balance of strengths and limitations, and their selection depends on drug properties, dosage form requirements, and intended therapeutic applications [36]. As these methods continue to evolve, their integration into pharmaceutical manufacturing is expected to become more mainstream, paving the way for truly personalized and efficient drug delivery solutions [37].

Table 1. Summary of Techniques: Comparative Table.

Technique	Processing Temp	Drug Stability	Resolution	Geometry Complexity	Key Application	References
FDM	High (~200°C)	Limited	Moderate	High	Oral tablets, polypills	[38, 39]
Inkjet	Low (room temp)	Excellent	High	Low	Films, orodispersibles	[40, 41]
SLA	Moderate (UV)	Moderate	Very High	Very High	Implants, microneedles	[42, 43]
SLS	High	Limited	High	High	Porous tablets, implants	[43, 44]
SSE/Hybrid	Low	Excellent	Moderate	Moderate	Hydrogels, transdermal, topicals	[45, 46]

3. Methods for Studying Aerobic Bacteria

3.1 Personalized Drug Formulations

One of the most impactful advantages of 3D printing in pharmaceutics is its ability to facilitate dose personalization. By controlling the design and content of each printed dosage form, healthcare professionals can tailor drug doses to the individual needs of patients, based on factors such as body weight, metabolism, disease stage, and genetic profile [23, 47]. This approach is particularly useful for drugs with a narrow therapeutic window or those requiring frequent dose adjustments.

3D printing also enables the development of age-specific dosage forms. Pediatric and geriatric patients often have difficulty swallowing traditional tablets or capsules [48]. Through 3D printing, it is possible to fabricate chewable tablets, orodispersible films, mini-tablets, and other formats in precise doses that enhance both safety and compliance. Additionally, drug formulations can be customized according to individual pharmacokinetic and pharmacodynamic profiles, leading to more effective and patient-centric treatment strategies [49, 50].

3.2 Complex and Novel Drug Delivery Systems

The architectural flexibility of 3D printing allows for the development of highly sophisticated drug delivery systems that were previously difficult or impossible to achieve with traditional manufacturing. Controlled-release formulations can be designed with specific internal geometries, such as multilayered structures or porous matrices, to regulate the timing and rate of drug release [51, 52]. These designs improve therapeutic outcomes by maintaining consistent drug levels and reducing dosing frequency.

3D printing also enables the fabrication of multi-drug polypills, which combine several active pharmaceutical ingredients in a single tablet, each compartmentalized or programmed for staggered release [53, 54]. This is especially beneficial for managing chronic diseases that require complex medication regimens, thereby enhancing patient adherence. Furthermore, chronotherapeutic and pulsatile delivery systems—designed to release drugs in synchronization with the body's circadian rhythms—can be easily created with 3D printing. Such systems are advantageous in conditions like hypertension, asthma, and rheumatoid arthritis, where drug timing significantly influences efficacy [55-57].

3.3 Rapid Prototyping and On-Demand Manufacturing

3D printing significantly streamlines the drug development process through rapid prototyping, allowing pharmaceutical scientists to design, fabricate, and test multiple formulation iterations in a short time frame. This accelerates formulation screening and optimization, reducing the overall time and cost associated with conventional development pathways [58].

Additionally, the technology offers promising solutions for on-demand manufacturing in clinical and emergency settings [59]. Customized drug products can be printed at the point of care such as hospitals, remote clinics, or disaster relief areas ensuring timely access to essential medications tailored to the patient's needs. This decentralized approach is particularly useful in scenarios where conventional supply chains are disrupted or insufficient. Moreover, small, personalized batches for clinical trials can be produced without the need for large-scale equipment, enhancing the efficiency of early-phase testing and regulatory submission [60-62].aldehydes via a tungsten-containing oxidoreductase, enhancing gut resilience [54,55]. Additionally aerobic bacteria modulate host immune responses, influencing inflammation ang gut barrier integrity. These interactions collectively shape microbiome composition, offering insights for micro-biome targeted therapies to improve gut health.

4. Materials for 3D-Printed Pharmaceuticals

The successful application of 3D printing in pharmaceutics relies heavily on the selection of appropriate materials, particularly active pharmaceutical ingredients (APIs) and excipients. Not all drug molecules are suitable for 3D printing, and their inclusion depends on thermal stability, solubility, molecular weight, and dose requirements [63, 64]. Drugs that are thermally stable, have a relatively low melting point, and are effective at small doses are preferred for techniques like fused deposition modeling (FDM) and selective laser sintering (SLS), which involve heat. Conversely, heat-sensitive or poorly water-soluble drugs may be better suited to room-temperature processes such as semi-solid extrusion or inkjet printing. Careful preformulation studies are essential to evaluate the compatibility of drugs with the intended printing method and excipient matrix [65-67].

A growing number of FDA-approved polymers and pharmaceutical excipients are now being explored for 3D printing applications as in Figure 1. These include commonly used polymers such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), ethyl cellulose, Eudragit variants, and polyvinyl alcohol (PVA). These polymers serve as carriers for APIs and provide structural support to printed dosage forms [68, 69]. PVA, in particular, is extensively used in FDM due to its excellent printability and water solubility, making it ideal for immediate-release formulations. For extended or controlled-release systems, Eudragit RS/RL or ethyl cellulose are often incorporated to regulate drug permeability. The choice of polymer affects not only the mechanical strength and printability of the dosage form but also its dissolution behavior and biocompatibility [70-72].

Beyond structural polymers, the role of functional excipients is critical in enhancing the printability and performance of 3D-printed pharmaceuticals [73]. Binders improve mechanical integrity, disintegrants facilitate tablet breakup in the gastrointestinal tract, and plasticizers lower the glass transition temperature (Tg) of polymers, making them easier to process [74]. Common plasticizers like triethyl citrate, sorbitol, and glycerol are used to improve filament flexibility and flow properties in FDM[75]. Additionally, lubricants such as magnesium stearate or stearic acid may be added to reduce friction during extrusion or layer deposition [76]. These excipients must be carefully selected and optimized to maintain formulation stability while ensuring compatibility with the thermal or mechanical stresses of the printing process.

Figure 1. It illustrates 3D printing in pharmaceutical applications.

Biodegradable and biocompatible materials are gaining traction in 3D-printed pharmaceuticals, especially for implantable and localized drug delivery systems [77]. Polymers like polylactic acid (PLA), polycaprolactone (PCL), and poly(lactic-co-glycolic acid) (PLGA) are favored for their ability to degrade into non-toxic byproducts within the body [78]. These materials are widely used in biomedical applications and are now being adapted for 3D printing of implants, scaffolds, and controlled-release drug reservoirs. The biodegradation rate can be adjusted by modifying the polymer composition, molecular weight, or crystallinity, offering tailored release profiles for specific therapeutic needs. Such materials are particularly advantageous in tissue engineering, cancer therapy, and localized antibiotic delivery [79, 80]. The incorporation of multi-functional and responsive materials is also an emerging trend in pharmaceutical 3D printing. Smart polymers that respond to stimuli such as pH, temperature, or enzymes can be integrated to create responsive drug delivery systems. For instance, pH-sensitive polymers like Eudragit L100 can be used to design enteric-coated dosage forms that protect drugs from gastric degradation and release them in the intestine depicted in Figure 2. Thermoresponsive polymers and hydrogels are being investigated for applications in oral, dermal, and mucosal delivery systems [81, 82]. These innovative materials not only enhance therapeutic outcomes but also allow for new dosage form designs that were previously unattainable using traditional methods.

Lastly, the safety, regulatory approval, and scalability of these materials remain crucial considerations. Although many of the excipients used in 3D printing are already included in the FDA's Generally Recognized As Safe (GRAS) list, their behavior under 3D printing conditions especially at high temperatures or when exposed to UV light, must be thoroughly evaluated. Regulatory guidelines are still evolving to address the unique characteristics of printed pharmaceuticals [83, 84]. Therefore, in addition to functional performance, materials must demonstrate consistent quality, biocompatibility, and reproducibility. Continued research into new excipients, printable polymers, and their interactions with APIs will be essential to fully unlock the potential of 3D printing in personalized and precision medicine [85].



Figure 2. It illustrates the application and importance of 3D Printing in various fields.

5. Emerging Trends and Innovations

5.1 4D Printing (Stimuli-Responsive Drug Systems)

One of the most exciting advancements in 3D printing is the evolution toward 4D printing, where printed objects not only have a three-dimensional form but can also change shape or properties over time in response to external stimuli [86]. In the context of pharmaceuticals, stimuli-responsive drug delivery systems are being explored, where the drug release profile can be triggered by factors such as pH, temperature, light, or enzymes [87, 88]. This innovation allows for the design of dynamic drug delivery systems that react to the physiological environment, offering significant advantages over traditional controlled-release formulations. For example, a 4D-printed tablet could release a drug in response to the acidic conditions of the stomach and continue to release the drug gradually in the more neutral environment of the intestine, enhancing bioavailability and targeting specific regions within the body. Stimuli-responsive systems also hold promises for creating self-adjusting implants or scaffolds for tissue engineering, furthering the potential of 4D printing in regenerative medicine [89-91].

5.2. Bioprinting for Drug Screening and Disease Models

Bioprinting is another innovative trend that has shown remarkable potential in pharmaceutical research. By utilizing living cells, bioprinting allows for the fabrication of 3D cellular constructs that mimic human tissues and organs, providing more accurate models for drug testing and disease studies [92, 93]. This approach offers a powerful alternative to traditional 2D cell cultures, which often fail to replicate the complexity of human biology. Bioprinted tissues can be used to screen drugs for efficacy and toxicity, reducing the reliance on animal models and improving the accuracy of preclinical testing. Additionally, bioprinted disease models, such as cancer or liver disease, offer an unprecedented platform for understanding disease mechanisms and testing novel therapies[94]. This innovation is expected to significantly accelerate the drug development pipeline, reducing time and costs while improving the predictability of drug responses.

5.3. AI/ML Integration for Formulation Design and Prediction

The integration of Artificial Intelligence (AI) and Machine Learning (ML) with 3D printing technology is set to revolutionize pharmaceutical formulation design and prediction. AI and ML algorithms can analyze vast amounts of data, including drug characteristics, patient demographics, and environmental factors, to predict the optimal formulation and dosage for an individual [95, 96]. These technologies can help identify patterns and relationships in complex datasets that may not be immediately obvious, allowing for the efficient design of custom drug formulations. In 3D printing, AI can optimize the printing process itself, fine-tuning parameters like extrusion rate, temperature, and print speed for better control over the final product. Furthermore, ML algorithms can assist in predictive modeling, simulating how different formulations will perform under various conditions, and accelerating the process of drug development and manufacturing [97, 98].

5.4. Digital Twin Models in Personalized Drug Development

The concept of digital twins—virtual replicas of physical objects or systems—has begun to make its way into personalized medicine, offering a highly innovative approach to drug development. By creating a digital twin of a patient's biological systems, including their disease state, pharmacokinetics, and response to medications, pharmaceutical companies can tailor drug formulations and therapies to individual patients with unprecedented precision [99]. This digital model evolves in real-time, allowing for continuous monitoring and adjustment of treatment strategies based on the patient's response. In combination with 3D printing, digital twins can be used to create personalized drug delivery systems, ensuring that drugs are released in the optimal manner for each patient [100]. The integration of digital twins into pharmaceutical development has the potential to enhance treatment efficacy, minimize adverse effects, and ultimately lead to more effective, individualized healthcare [101].

5.5. Nanoparticle and Nanocomposite Integration for Enhanced Drug Delivery

A notable area of innovation in 3D printing is the incorporation of nanoparticles and nanocomposites into drug delivery systems. The use of nanoscale materials enhances the properties of printed drugs, including increased solubility, stability, and targeted delivery. Nanoparticles can be used as carriers for hydrophobic drugs, improving their bioavailability and enabling controlled, sustained release [102]. In addition, nanocomposites combination of nanoparticles with biodegradable polymers offer unique advantages in drug delivery, such as improved mechanical strength, biocompatibility, and the ability to encapsulate a wide range of therapeutic agents [103]. This integration of nanotechnology with 3D printing allows for the fabrication of complex drug delivery systems, such as multilayered structures with distinct release profiles or nanoscale coatings for targeted drug release. This field holds significant promises in developing next-generation therapies, particularly for chronic diseases, cancer, and neurodegenerative conditions [104, 105].

5.6. Sustainability and Green Manufacturing in 3D Printing

Sustainability is an increasingly important focus in pharmaceutical manufacturing, and 3D printing offers new avenues for green manufacturing. By reducing material waste through layer-by-layer additive processes, 3D printing can significantly minimize the environmental impact compared to traditional manufacturing methods, which often require molds and large quantities of raw material [106]. Moreover, the ability to produce on-demand reduces the need for large-scale production and inventory storage, potentially lowering the carbon footprint associated with drug manufacturing and distribution. Researchers are also exploring the use of renewable, biodegradable, and non-toxic materials for 3D printing, contributing to a more sustainable pharmaceutical industry. As the focus on environmental impact grows, the incorporation of eco-friendly materials and practices into pharmaceutical 3D printing will become an essential consideration for manufacturers and regulatory bodies alike [107].

6. Challenges, Limitations, and Future Directions

While 3D printing has the potential to revolutionize pharmaceutical manufacturing, several challenges remain that must be addressed to fully realize its promise. Technological barriers, such as limitations in hardware precision and material compatibility, hinder the development of high-quality printed formulations. Moreover, there is significant regulatory uncertainty, with the lack of harmonized standards making it difficult to ensure consistent safety, efficacy, and quality across different regions. Economic feasibility remains a concern, as the costs associated with 3D printing equipment, specialized materials, and production processes are still relatively high compared to traditional manufacturing methods. Additionally, the stability and shelf-life of printed pharmaceuticals can be variable, requiring further research to ensure these formulations maintain their potency over time.

Looking ahead, the future directions for 3D printing in pharmaceuticals are promising, particularly in the integration of this technology within hospital and pharmacy settings for on-demand, personalized medication production. This could provide more customized treatments, especially for patients with rare diseases or complex needs. Furthermore, fostering collaborative frameworks between academia, industry, and regulators will be crucial to address the current challenges and establish standardized protocols. As technology advances, AI and machine learning could be incorporated to enhance formulation design and drug delivery systems, ensuring that 3D printing becomes an integral part of the next-generation pharmaceutical ecosystem, enabling a more personalized, efficient, and patient-centered approach to healthcare.

7. Conclusion

In conclusion, 3D printing has undeniably emerged as a transformative technology in pharmaceutical research, offering the potential to revolutionize drug development, formulation, and delivery. Its ability to enable personalized therapies, accelerate drug design, and provide on-demand drug manufacturing holds great promise for addressing the challenges of conventional drug development processes. However, technological, regulatory, and economic hurdles remain, and the integration of 3D printing into mainstream pharmaceutical manufacturing will require continued innovation, collaboration, and standardization. As we move toward a more patient-centric healthcare system, 3D printing is poised to play a central role in shaping the future of pharmaceutical therapeutics, offering safer, more effective, and individualized treatment options for patients worldwide. research and involve overcoming current limitations, expanding research, and ensuring regulatory alignment to fully unlock the potential of 3D printing in the pharmaceutical industry.

Acknowledgement:

Authors would like to acknowledge Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan.

Conflict of Interest

Authors have no conflict of interest to declare.

References

[1] Bernatoniene, J., et al., The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals. *Pharmaceutics*, 2025. **17**: p. 390.

[2] Dos Santos, J., et al., Eudragit(®): A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. *Pharmaceutics*, 2021. **13(9)**.

[3] Vora, L.K., et al., Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*, 2023. **15(7)**.

[4] Milliken, R.L., et al., Application of 3D printing in early phase development of pharmaceutical solid dosage forms. *International Journal of Pharmaceutics*, 2024. **653**: p. 123902.

[5] Kapoor, Y., et al., Flexibility in Drug Product Development: A Perspective. *Molecular Pharmaceutics*, 2021. **18**.

[6] Lopez, F.L., et al., Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. *Expert Opin Drug Deliv*, 2015. **12(11)**: p. 1727–1740.

[7] Racaniello, G.F., et al., Innovative Pharmaceutical Techniques for Paediatric Dosage Forms: A Systematic Review on 3D Printing, Prilling/Vibration and Microfluidic Platform. *Journal of Pharmaceutical Sciences*, 2024. **113(7)**: p. 1726–1748.

[8] Kulsoom, J., et al., Nano-Based Drug Delivery Systems in Plants, in *Revolutionizing Agriculture: A Comprehensive Exploration of Agri-Nanotechnology*, R. Shahzad, et al., Editors. 2024, *Springer Nature Switzerland*: Cham. p. 307–323.

[9] Hasan, N., et al., Recent advancements of nitric oxide-releasing hydrogels for wound dressing applications. *Journal of Pharmaceutical Investigation*, 2023. **53(6)**: p. 781–801.

[10] Ullah, M., et al., Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. *Chemosphere*, 2021. **275**: p. 129968.

[11] Khan, S.U., et al., Advances and Challenges for GWAS Analysis in Cardiac Diseases: A Focus on Coronary Artery Disease (CAD). *Curr Probl Cardiol*, 2023. **48(9)**: p. 101821.

[12] Ullah, M., et al., Smart Technologies used as Smart Tools in the Management of Cardiovascular Disease and their Future Perspective. *Curr Probl Cardiol*, 2023. **48(11)**: p. 101922.

[13] Safdar, M., et al., Genomic insights into heart health: Exploring the genetic basis of cardiovascular disease. *Curr Probl Cardiol*, 2024. **49(1 Pt C)**: p. 102182.

[14] Khan, S.U., et al., Single-cell RNA Sequencing (scRNA-seq): Advances and Challenges for Cardiovascular Diseases (CVDs). *Curr Probl Cardiol*, 2024. **49(2)**: p. 102202.

[15] Ullah, A., M. Ullah, and S.I. Lim, Recent advancements in nanotechnology based drug delivery for the management of cardiovascular disease. *Curr Probl Cardiol*, 2024. **49(4)**: p. 102396.

[16] Khan, M.A., et al., 3D printing technology and its revolutionary role in stent implementation in cardiovascular disease. *Curr Probl Cardiol*, 2024. **49(6)**: p. 102568.

[17] Safdar, M., et al., Microbiome miracles and their pioneering advances and future frontiers in cardiovascular disease. *Curr Probl Cardiol*, 2024. **49(9)**: p. 102686.

[18] Amekyeh, H., F. Tarlochan, and N. Billa, Practicality of 3D Printed Personalized Medicines in Therapeutics. *Front Pharmacol*, 2021. **12**: p. 646836.

[19] Alifah, N., et al., Development of Clindamycin-Releasing Polyvinyl Alcohol Hydrogel with Self-Healing Property for the Effective Treatment of Biofilm-Infected Wounds. *Gels*, 2024. **10(7)**.

[20] Zeb, F., et al., Nutrition and Dietary Intervention in Cancer: Gaps, Challenges, and Future Perspectives. *Cancer Treat Res*, 2024. **191**: p. 281–307.

[21] Ullah, M., et al., Clindamycin-Loaded Polyhydroxyalkanoate Nanoparticles for the Treatment of Methicillin-Resistant *Staphylococcus aureus*-Infected Wounds. *Pharmaceutics*, 2024. **16(10)**.

[22] Hasan, N., et al., Nitric oxide-releasing self-healing hydrogel for antibacterial and antibiofilm efficacy against polymicrobial infection. *Future Microbiol*, 2024. **19(18)**: p. 1559–1571.

[23] Ali, H., et al., Induction of Pharmacists in Accident and Emergency Departments and Hospitals in Pakistan: A Case Study. 2021.

[24] Hamayun, S., et al., Rational Therapeutic Approaches for the Management of Congestive Cardiac Failure. *Journal of Bashir Institute of Health Sciences*, 2023. **4**: p. 62–68.

[25] Wang, S., et al., A Review of 3D Printing Technology in Pharmaceutics: Technology and Applications, Now and Future. *Pharmaceutics*, 2023. **15(2)**.

[26] Peng, H., et al., 3D printing processes in precise drug delivery for personalized medicine. *Biofabrication*, 2024. **16(3)**.

[27] Amin, Z., et al., *Fundamentals of Nanotechnology*. 2024. p. 1–16.

[28] Ullah, M., et al., Cancer nanomedicine: Smart arsenal in the war against cancer. *Inorganic Chemistry Communications*, 2025. **174**: p. 114030.

[29] Varghese, R., et al., 3D printing in the pharmaceutical sector: Advances and evidences. *Sensors International*, 2022. **3**: p. 100177.

[30] Aftab, M., et al., Recent Trends and Future Directions in 3D Printing of Biocompatible Polymers. *Journal of Manufacturing and Materials Processing*, 2025. **9**: p. 129.

[31] Barbato, L., et al., Cancer Stem Cells and Targeting Strategies. *Cells*, 2019. **8(8)**.

[32] Xu, X., et al., Stereolithography (SLA) 3D printing of an antihypertensive polyprintlet: Case study of an unexpected photopolymer-drug reaction. 2020. **33**: p. 101071.

[33] Al Bander, Z., et al., The Gut Microbiota and Inflammation: An Overview. *Int J Environ Res Public Health*, 2020. **17(20)**.

[34] Shammout, H., et al., An overview of selective laser sintering technology: principles, formulations, applications and promising potentials in pharmaceutics. *Journal of Drug Delivery Science and Technology*, 2025: p. 107166.

[35] Ali, H., et al., A Systematic Review: Clinical Manifestations of Diabetes Mellitus and The Role of Pharmacists in Management of Type II Diabetes. *Journal of Women Medical and Dental College*, 2023. **2(1)**.

[36] Cerveto, et al., The promising role of semi-solid extrusion technology in custom drug formulation for pediatric medicine. *International Journal of Bioprinting*, 2024: p. 4063.

[37] Flamia Azevedo, B., A. Rocha, and A. Pereira, Hybrid approaches to optimization and machine learning methods: a systematic literature review. *Machine Learning*, 2024. **113**.

[38] Muneeb, U., A Case Study: Psychophysiological Impact of Polycystic Ovarian Syndrome and its Management in Pakistani Women. *Journal of Women Medical and Dental College*, 2022. **1(1)**.

[39] Safdar, M., et al., The Evolving Landscape of Biosafety and Biosecurity: A Review of International Guidelines and Best Practices. *Journal of Women Medical and Dental College*, 2023. **2(2)**.

[40] Patel, N. and A. Serajuddin, Development of FDM 3D-printed tablets with rapid drug release, high drug-polymer miscibility and reduced printing temperature by applying the acid-base supersolubilization (ABS) principle. *International Journal of Pharmaceutics*, 2021. **600**: p. 120524.

[41] Borandeh, S., et al., Polymeric drug delivery systems by additive manufacturing. *Advanced Drug Delivery Reviews*, 2021. **173**: p. 349–373.

[42] Rodríguez-Pombo, L., et al., Customizable orodispersible films: Inkjet printing and data matrix encoding for personalized hydrocortisone dosing. *International Journal of Pharmaceutics*, 2024. **655**: p. 124005.

[43] Brokmann, F., et al., Potential and limitations of patient-specific inkjet printing on orodispersible films: A critical and practical look at innovation barriers for pharmaceutical applications. *Journal of Drug Delivery Science and Technology*, 2025. **106**: p. 106707.

[44] Lyu, S., et al., Going below and beyond the surface: Microneedle structure, materials, drugs, fabrication, and applications for wound healing and tissue regeneration. *Bioact Mater*, 2023. **27**: p. 303–326.

[45] Huo, T., et al., Advancing microneedle technology for multiple distinct target organs drug delivery through 3D printing: a comprehensive review. *Advanced Composites and Hybrid Materials*, 2025. **8(3)**: p. 266.

[46] Rehman, K.u., et al., The Antibacterial Assessment of Biofabricated Magnesium Oxide Nanoparticles (MgO NPs) using *Conocarpus erectus* Leaf Extract. *Journal of Women Medical and Dental College*, 2022. **1(2)**.

[47] Bácskay, I., et al., The Evolution of the 3D-Printed Drug Delivery Systems: A Review. *Pharmaceutics*, 2022. **14(7)**.

[48] Nawaz, K., et al., Role of Nutrition in the Management of Inflammatory Bowel Disease. *Recent Progress in Nutrition*, 2025. **05(01)**: p. 002.

[49] Khaled, S.A., et al., 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *J Control Release*, 2015. **217**: p. 308–314.

[50] Breier, D. and D. Peer, Genome editing in cancer: Challenges and potential opportunities. *Bioactive Materials*, 2023. **21**: p. 394–402.

[51] Butler, C.T., et al., Chrono-tailored drug delivery systems: recent advances and future directions. *Drug Deliv Transl Res*, 2024. **14(7)**: p. 1756–1775.

[52] Khan, S.U., et al., Nanotherapeutic approaches for transdermal drug delivery systems and their biomedical applications. *European Polymer Journal*, 2024. **207**: p. 112819.

[53] Hasan, N., et al., Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential. *Results in Chemistry*, 2025. **14**: p. 102068.

[54] Bernatoniene, J., et al., The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals. *Pharmaceutics*, 2025. **17**: p. 390.

[55] Junaid, S.B., et al., Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. *Healthcare (Basel)*, 2022. **10(10)**.

[56] Årdal, C., et al., Supply chain transparency and the availability of essential medicines. *Bull World Health Organ*, 2021. **99(4)**: p. 319–320.

[57] Ullah, M., et al., 3D printing technology: A new approach for the fabrication of personalized and customized pharmaceuticals. *European Polymer Journal*, 2023. **195**: p. 112240.

[58] Ullah, M., et al., Modified gold and polymeric gold nanostructures: Toxicology and biomedical applications. *Colloid and Interface Science Communications*, 2021. **42**: p. 100412.

[59] Paccione, N., et al., Application of 3D printing on the design and development of pharmaceutical oral dosage forms. *Journal of Controlled Release*, 2024. **373**: p. 463–480.

[60] Ullah, M., et al., Stent as a Novel Technology for Coronary Artery Disease and Their Clinical Manifestation. *Curr Probl Cardiol*, 2023. **48(1)**: p. 101415.

[61] Abdella, S., et al., 3D Printing of Thermo-Sensitive Drugs. *Pharmaceutics*, 2021. **13(9)**.

[62] Abbas, A., et al., A Comprehensive Review: Epidemiological Strategies, Catheterization and Biomarkers used as a Bioweapon in Diagnosis and Management of Cardio Vascular Diseases. *Curr Probl Cardiol*, 2023. **48(7)**: p. 101661.

[63] Gueche, Y.A., et al., Selective Laser Sintering (SLS), a New Chapter in the Production of Solid Oral Forms (SOFs) by 3D Printing. *Pharmaceutics*, 2021. **13(8)**.

[64] Pereira, G.G., et al., Polymer Selection for Hot-Melt Extrusion Coupled to Fused Deposition Modelling in Pharmaceutics. *Pharmaceutics*, 2020. **12(9)**.

[65] Ullah, M., et al., Shaping the Future of Cardiovascular Disease by 3D Printing Applications in Stent Technology and its Clinical Outcomes. *Curr Probl Cardiol*, 2024. **49(1 Pt A)**: p. 102039.

[66] Dos Santos, J., et al., Eudragit(®): A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. *Pharmaceutics*, 2021. **13(9)**.

[67] Couți, N., et al., Polyvinyl Alcohol, a Versatile Excipient for Pharmaceutical 3D Printing. *Polymers (Basel)*, 2024. **16(4)**.

[68] Fanous, M., et al., Development of Immediate Release 3D-Printed Dosage Forms for Poorly Water-Soluble Drugs by Fused Deposition Modeling: Study of Morphology, Solid State and Dissolution. *International Journal of Pharmaceutics*, 2021. **599**: p. 120417.

[69] Jain, A., et al., Role of Polymers in 3D Printing Technology for Drug Delivery - An Overview. *Curr Pharm Des*, 2018. **24(42)**: p. 4979–4990.

[70] Muehlenfeld, C., et al., Excipients in Pharmaceutical Additive Manufacturing: A Comprehensive Exploration of Polymeric Material Selection for Enhanced 3D Printing. *Pharmaceutics*, 2024. **16(3)**.

[71] Tomuță, I. and A. Porfire, Printability of Pharmaceutical Polymers: Issues and Solutions. 2023. p. 69–112.

[72] Muehlenfeld, C., et al., Polymers for Pharmaceutical 3D Printing: Printability and Critical Insight into Material Properties. 2023. p. 97–137.

[73] Picco, C.J., et al., 3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs. *Drug Deliv*, 2022. **29(1)**: p. 1038–1048.

[74] Makadia, H.K. and S.J. Siegel, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. *Polymers (Basel)*, 2011. **3(3)**: p. 1377–1397.
[75] Song, R., et al., Current development of biodegradable polymeric materials for biomedical applications. *Drug Des Devel Ther*, 2018. **12**: p. 3117–3145.
[76] Varma, M., B. Kandasubramanian, and S. Ibrahim, 3D printed scaffolds for biomedical applications. *Materials Chemistry and Physics*, 2020. **255**: p. 123642.
[77] Bajgiran, N.K., Y. Ahmadi, and S. Majidi, Smart nanoparticles for responsive drug delivery in Diabetes: Advances, Challenges, and future Perspectives. *International Journal of Pharmaceutics*, 2025. **681**: p. 125817.
[78] Singh, J. and P. Nayak, pH-responsive Polymers for Drug Delivery: Trends and Opportunities. *Journal of Polymer Science*, 2023. **61**: p. 1–23.
[79] Kagita, T., et al., Advancing 3D printing for personalized pediatric medicines: quality, safety, and Good Manufacturing Practice compliance. *Translational and Regulatory Sciences*, 2025.
[80] Vaz, V.M. and L. Kumar, 3D Printing as a Promising Tool in Personalized Medicine. *AAPS PharmSciTech*, 2021. **22(1)**: p. 49.
[81] Serrano, D.R., et al., 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. *Pharmaceutics*, 2023. **15(2)**.
[82] Parhi, R. and A. Garg, Recent Advances in 4D Printing: A Review of Current Smart Materials, Technologies, and Drug Delivery Systems. *Curr Pharm Des*, 2025. **31(15)**: p. 1180–1204.
[83] Ramezani, M. and Z. Mohd Ripin, 4D Printing in Biomedical Engineering: Advancements, Challenges, and Future Directions. *J Funct Biomater*, 2023. **14(7)**.
[84] Parhi, R. and A. Garg, Recent Advances in 4D Printing: A Review of Current Smart Materials, Technologies, and Drug Delivery Systems. *Current Pharmaceutical Design*, 2024. **31**.
[85] Panraksa, P., et al., 4D printing of shape-memory polymer-based floating tablets via fused deposition modelling: Transformable helical structure to tablet-like form. *Journal of Drug Delivery Science and Technology*, 2025. **104**: p. 106534.
[86] Tran, T.S., et al., 4D Printing of Hydrogels: Innovation in Material Design and Emerging Smart Systems for Drug Delivery. *Pharmaceuticals (Basel)*, 2022. **15(10)**.
[87] Beck, R., et al., 3D printed tablets loaded with polymeric nanocapsules: An innovative approach to produce customized drug delivery systems. *International Journal of Pharmaceutics*, 2017. **528**.
[88] Lam, E.H.Y., et al., 3D Bioprinting for Next-Generation Personalized Medicine. *Int J Mol Sci*, 2023. **24(7)**.
[89] Tripathi, S., et al., 3D bioprinting and its innovative approach for biomedical applications. *MedComm (2020)*, 2023. **4(1)**: p. e194.
[90] Maltman, D. and S. Przyborski, Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. *Biochemical Society Transactions*, 2010. **38**: p. 1072–1075.
[91] Kassa, F.M., et al., Use of Computational Intelligence in Customizing Drug Release from 3D-Printed Products: A Comprehensive Review. *Pharmaceutics*, 2025. **17(5)**.
[92] Ali, K.A., et al., Influence of artificial intelligence in modern pharmaceutical formulation and drug development. *Future Journal of Pharmaceutical Sciences*, 2024. **10(1)**: p. 53.
[93] Sani, A., A. Zolfagharian, and A. Kouzani, Artificial Intelligence-Augmented Additive Manufacturing: Insights on Closed-Loop 3D Printing. *Advanced Intelligent Systems*, 2024. **6**.
[94] Chakraborty, R., et al., Strategies To Modify the Surface and Bulk Properties of 3D-Printed Solid Scaffolds for Tissue Engineering Applications. *ACS Omega*, 2023. **8(6)**: p. 5139–5156.
[95] Sun, T., et al., The Digital Twin in Medicine: A Key to the Future of Healthcare? *Front Med (Lausanne)*, 2022. **9**: p. 907066.
[96] Katsoulakis, E., et al., Digital twins for health: a scoping review. *npj Digital Medicine*, 2024. **7(1)**: p. 77.
[97] Papachristou, K., et al., Digital Twins' Advancements and Applications in Healthcare, Towards Precision Medicine. *J Pers Med*, 2024. **14(11)**.
[98] Jain, K., et al., 3D Printing in Development of Nanomedicines. *Nanomaterials*, 2021. **11**: p. 420.
[99] Ma, X., et al., Nanotechnology in healthcare, and its safety and environmental risks. *Journal of Nanobiotechnology*, 2024. **22(1)**: p. 715.
[100] Bernatoniene, J., M. Plieskis, and K. Petrikonis, Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies. *Pharmaceutics*, 2025. **17(3)**.
[101] Khan, F., et al., 3D Printing Technology in Customized Drug Delivery System: Current State of the Art, Prospective and the Challenges. *Current Pharmaceutical Design*, 2019. **25**.
[102] Pongwisuthiruchte, A. and P. Potiyaraj, Challenges and innovations in sustainable 3D printing. *Materials Today Sustainability*, 2025. **31**: p. 101134.
[103] Al Rashid, A. and M. Koç, Additive manufacturing for sustainability and circular economy: needs, challenges, and opportunities for 3D printing of recycled polymeric waste. *Materials Today Sustainability*, 2023. **24**: p. 100529.